Triple-negative breast cancer trials in China

In China 133 Also abroad 423

133 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance
Where
Tianjin
Age
18 years to 75 years
People
72
Run by
Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07321015
Phase 1Taking people
A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
Where
Jinan
Age
18 years to 75 years
People
299 worldwide
Run by
Huahui Health
See details and how to joinNCT07623369
No phaseTaking people
Establishment of a Multi-omics Prediction Model for Early Triple-negative Breast Cancer Based on UPGRADE-TNBC Study
Where
Beijing
Age
18 years to 75 years
People
32
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07773818
Phase 2/3Enrolling by invitation
Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TNBC）
Where
Beijing
Age
18 years to 75 years
People
32
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT06910072
Phase 2/3Taking people
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Where
Changsha, Guangzhou
Age
18 years to 75 years
People
446
Run by
BeBetter Med Inc
See details and how to joinNCT07544056
Phase 2/3Taking people
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Where
Anyang, Beijing, Changchun, Changsha, Chengdu, Fuzhou, Fyzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanning, Qingdao, Shenyang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Zhengzhou
Age
18 years and over
People
600 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06926868 · EU 2024-519871-24-00
Phase 2Not yet taking people in China
Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer
Where
Harbin
Age
18 years to 100 years
People
120
Run by
Harbin Medical University
See details and how to joinNCT07752550
Phase 1/2Taking people
Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study
Where
Guiyang
Age
18 years to 70 years
People
30
Run by
Liu Shu
See details and how to joinNCT07739485
Phase 2Taking people
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
Where
Shanghai
Age
18 years to 75 years
People
52
Run by
Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT06471205
Phase 1Taking people
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Where
Beijing, Shanghai
Age
18 years and over
People
714 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00
No phaseTaking people
Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC
Where
Shanghai
Age
18 years and over
People
30
Run by
Fudan University
See details and how to joinNCT07705438
Phase 2Taking people
A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.
Where
Shanghai
Age
18 years to 80 years
People
95
Run by
Fudan University
See details and how to joinNCT06889610
Phase 2Taking people
Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-negative Breast Cancer.
Where
Beijing
Age
18 years and over
People
150
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT06771609
Phase 2Not yet taking people in China
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
Where
Beijing, Harbin
Age
18 years to 80 years
People
227
Run by
GV20 Therapeutics
See details and how to joinNCT07623642
Phase 3Not yet taking people in China
Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations
Where
Shanghai
Age
18 years and over
People
420
Run by
Fudan University
See details and how to joinNCT07628504
No phaseTaking people
A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer.
Where
Nanjing
Age
18 years to 75 years
People
59
Run by
The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07622836
Phase 2Taking people
Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases
Where
Shanghai
Age
18 years and over
People
24
Run by
Fudan University
See details and how to joinNCT07623577
Phase 2Taking people
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Where
Shanghai
Age
18 years to 70 years
People
716
Run by
Fudan University
See details and how to joinNCT05582499
Phase 2Taking people
QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer
Where
Nanjing
Age
18 years to 75 years
People
34
Run by
Jiangsu Cancer Institute & Hospital
See details and how to joinNCT07601178
Phase 2Taking people
Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.
Where
Nanjing
Age
18 years to 70 years
People
58
Run by
The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07394387
Phase 2Taking people
Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)
Where
Shanghai
Age
18 years to 70 years
People
46
Run by
RenJi Hospital
See details and how to joinNCT07283692
Phase 3Not yet taking people in China
A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer
Where
Shanghai
Age
18 years to 75 years
People
356
Run by
Mabwell (Shanghai) Bioscience Co., Ltd.
See details and how to joinNCT07556848
No phaseTaking people
Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer
Where
Shanghai
Age
18 years to 75 years
People
300
Run by
Fudan University
See details and how to joinNCT07551050
Phase 3Taking people
Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
Where
Changsha, Guangzhou, Guiyang, Shanghai, Wuhan, Yichang, Yongzhou
Age
18 years to 70 years
People
246
Run by
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT06889688
Phase 2Taking people
FMD and Neoadjuvant Chemo-immunotherapy in TNBC
Where
Guangzhou
Age
18 years to 70 years
People
80
Run by
Sun Yat-sen University
See details and how to joinNCT07378306